Kathleen M Giacomini

List of Publications by Citations

Source: https://exaly.com/author-pdf/1457098/kathleen-m-giacomini-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142 papers	10,303 citations	46 h-index	100 g-index
151 ext. papers	11,800 ext. citations	7.6 avg, IF	5.91 L-index

#	Paper	IF	Citations
142	Membrane transporters in drug development. *Nature Reviews Drug Discovery*, **2010**, 9, 215-36	64.1	2464
141	Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. *Journal of Clinical Investigation*, **2007**, 117, 1422-31	15.9	673
140	SLC transporters as therapeutic targets: emerging opportunities. *Nature Reviews Drug Discovery*, **2015**, 14, 543-60	64.1	363
139	Cloning and functional expression of a human liver organic cation transporter. *Molecular Pharmacology*, **1997**, 51, 913-21	4.3	343
138	Organic cation transporters are determinants of oxaliplatin cytotoxicity. *Cancer Research*, **2006**, 66, 8847-57	11.1	339
137	The concentrative nucleoside transporter family, SLC28. *Pflugers Archiv European Journal of Physiology*, **2004**, 447, 728-34	4.6	304
136	Metformin pathways: pharmacokinetics and pharmacodynamics. *Pharmacogenetics and Genomics*, **2012**, 22, 820-7	1.9	256
135	Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5902-7	11.5	241
134	Renal transporters in drug development. *Annual Review of Pharmacology and Toxicology*, **2013**, 53, 503-29	17.9	226
133	Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5896-901	11.5	208
132	cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8902-7	11.5	198
131	Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. *Pharmacogenetics and Genomics*, **2009**, 19, 497-504	1.9	184
130	Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. *Pharmacogenetics and Genomics*, **2002**, 12, 395-405		169
129	OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 9983-8	11.5	155
128	Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. *Molecular Cancer Therapeutics*, **2011**, 10, 531-9	6.1	145
127	Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. *Pharmacogenetics and Genomics*, **2010**, 20, 687-99	1.9	145
126	Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 5480-5	11.5	129

125	Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. *Journal of Medicinal Chemistry*, **2011**, 54, 4548-58	8.3	117
124	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 890-899	6.1	113
123	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nature Genetics*, **2016**, 48, 1055-1059	36.3	108
122	Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 15810-5	11.5	101
121	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. *Journal of Medicinal Chemistry*, **2013**, 56, 781-795	8.3	100
120	Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. *Molecular Pharmacology*, **2008**, 73, 1151-8	4.3	91
119	Metformin pharmacogenomics: current status and future directions. *Diabetes*, **2014**, 63, 2590-9	0.9	90
118	Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. *Journal of Pharmacology and Experimental Therapeutics*, **2007**, 322, 695-700	4.7	88
117	Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. *Pharmacogenomics Journal*, **2009**, 9, 127-36	3.5	87
116	A genome-wide association study of bronchodilator response in Latinos implicates rare variants. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 370-8	11.5	84
115	Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). *Pharmacogenetics and Genomics*, **2005**, 15, 201-9	1.9	81
114	The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. *American Journal of Physiology - Renal Physiology*, **2006**, 290, F905-12	4.3	78
113	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 836-864	6.1	77
112	Transporters Involved in Metformin Pharmacokinetics and Treatment Response. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2245-2250	3.9	72
111	Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. *Clinical Pharmacokinetics*, **2014**, 53, 283-293	6.2	67
110	Arginine 454 and lysine 370 are essential for the anion specificity of the organic anion transporter, rOAT3. *Biochemistry*, **2001**, 40, 5511-20	3.2	67
109	Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. *Molecular Cancer Therapeutics*, **2010**, 9, 1058-69	6.1	66
108	Molecular modeling and ligand docking for solute carrier (SLC) transporters. *Current Topics in Medicinal Chemistry*, **2013**, 13, 843-56	3	65

107	Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. *Molecular Pharmacology*, **2015**, 88, 75-83	4.3	62
106	Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). *Molecular Pharmaceutics*, **2015**, 12, 4301-10	5.6	61
105	Identification and Quantitative Assessment of Uremic Solutes as Inhibitors of Renal Organic Anion Transporters, OAT1 and OAT3. *Molecular Pharmaceutics*, **2016**, 13, 3130-40	5.6	61
104	Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 803-817	6.1	60
103	Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. *Nature Reviews Drug Discovery*, **2017**, 16, 1	64.1	59
102	Interaction of nucleoside analogues with the sodium-nucleoside transport system in brush border membrane vesicles from human kidney. *Pharmaceutical Research*, **1993**, 10, 423-6	4.5	55
101	Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient. *Clinical Pharmacology and Therapeutics*, **1980**, 27, 665-70	6.1	54
100	Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. *Pharmacogenetics and Genomics*, **2009**, 19, 770-80	1.9	52
99	Rapid Method To Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in Organic Cation Transporter 1-Transfected Human Embryonic Kidney 293 Cells. *Drug Metabolism and Disposition*, **2016**, 44, 356-64	4	46
98	Molecular determinants of substrate selectivity in Na+-dependent nucleoside transporters. *Journal of Biological Chemistry*, **1997**, 272, 28845-8	5.4	46
97	Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). *Molecular Pharmacology*, **2006**, 70, 1602-11	4.3	46
96	A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1083-1092	6.1	45
95	The role of ATM in response to metformin treatment and activation of AMPK. *Nature Genetics*, **2012**, 44, 359-60	36.3	44
94	The effect of probenecid on the renal elimination of cimetidine. *Clinical Pharmacology and Therapeutics*, **1989**, 45, 444-52	6.1	44
93	Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. *Molecular Pharmaceutics*, **2013**, 10, 650-63	5.6	41
92	High selectivity of the □aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach. *Journal of Biological Chemistry*, **2012**, 287, 37745-56	5.4	41
91	Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). *Journal of Pharmaceutical Sciences*, **2013**, 102, 3451-7	3.9	41
90	The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. *Clinical Pharmacology and Therapeutics*, **1989**, 46, 408-19	6.1	41

89	Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1). *Journal of Medicinal Chemistry*, **2017**, 60, 2685-2696	8.3	39
88	Pharmacogenomics and patient care: one size does not fit all. *Science Translational Medicine*, **2012**, 4, 153ps18	17.5	39
87	Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). *Pharmacogenetics and Genomics*, **2007**, 17, 773-82	1.9	39
86	Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1). *Journal of Medicinal Chemistry*, **2018**, 61, 7358-7373	8.3	38
85	The pharmacokinetics of the enantiomers of atenolol. *Clinical Pharmacology and Therapeutics*, **1989** , 45, 403-10	6.1	38
84	The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin. *Clinical Pharmacokinetics*, **2016**, 55, 711-21	6.2	37
83	Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. *Pharmaceutical Research*, **2011**, 28, 610-25	4.5	36
82	The activities of drug inactive ingredients on biological targets. *Science*, **2020**, 369, 403-413	33.3	34
81	Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. *PLoS ONE*, **2009**, 4, e6942	3.7	33
80	Prediction and validation of enzyme and transporter off-targets for metformin. *Journal of Pharmacokinetics and Pharmacodynamics*, **2015**, 42, 463-75	2.7	32
79	Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 758-760	6.1	31
78	Genome-wide discovery of drug-dependent human liver regulatory elements. *PLoS Genetics*, **2014**, 10, e1004648	6	30
77	Genomic Characterization of Metformin Hepatic Response. *PLoS Genetics*, **2016**, 12, e1006449	6	30
76	LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2616-2621	2.9	30
75	Molecular Mechanisms for Species Differences in Organic Anion Transporter 1, OAT1: Implications for Renal Drug Toxicity. *Molecular Pharmacology*, **2018**, 94, 689-699	4.3	29
74	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 5000-5006	2.9	29
73	A research roadmap for next-generation sequencing informatics. *Science Translational Medicine*, **2016**, 8, 335ps10	17.5	29
72	Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. *PLoS Biology*, **2018**, 16, e2002907	9.7	29

71	Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients. *Clinical Pharmacology and Therapeutics*, **1980**, 27, 508-14	6.1	27
70	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. *Clinical and Translational Science*, **2019**, 12, 388-399	4.9	26
69	Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt. *Clinical Pharmacology and Therapeutics*, **1980**, 28, 417-24	6.1	24
68	A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. *Pharmacogenetics and Genomics*, **2015**, 25, 82-92	1.9	23
67	The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. *Clinical Pharmacokinetics*, **2016**, 55, 495-506	6.2	22
66	Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue. *PLoS Biology*, **2019**, 17, e2006571	9.7	21
65	A conserved role of the insulin-like signaling pathway in diet-dependent uric acid pathologies in Drosophila melanogaster. *PLoS Genetics*, **2019**, 15, e1008318	6	20
64	Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans. *Frontiers in Pharmacology*, **2016**, 7, 135	5.6	20
63	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1428-1440	0.9	18
62	Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F767-75	4.3	18
61	Genetic variation in human aquaporins and effects on phenotypes of water homeostasis. *Human Mutation*, **2008**, 29, 1108-17	4.7	18
60	The Effect of Uremic Solutes on the Organic Cation Transporter 2. *Journal of Pharmaceutical Sciences*, **2017**, 106, 2551-2557	3.9	17
59	Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 233-242	6.1	17
58	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 57-61	6.1	17
57	Stereoselective interactions of organic cations with the organic cation transporter in OK cells. *Pharmaceutical Research*, **1993**, 10, 1169-73	4.5	16
56	Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 623-631	6.1	15
55	Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 16009-16018	11.5	15
54	Drug-nutrient interactions: discovering prescription drug inhibitors of the thiamine transporter ThTR-2 (SLC19A3). *American Journal of Clinical Nutrition*, **2020**, 111, 110-121	7	15

53	Unraveling the functional role of the orphan solute carrier, SLC22A24 in the transport of steroid conjugates through metabolomic and genome-wide association studies. *PLoS Genetics*, **2019**, 15, e1008208	6	14
52	PharmGKB summary: very important pharmacogene information for ABCG2. *Pharmacogenetics and Genomics*, **2017**, 27, 420-427	1.9	14
51	Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. *Pharmaceutical Research*, **2003**, 20, 319-23	4.5	14
50	Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration. *Pharmaceutical Research*, **1984**, 1, 179-81	4.5	14
49	Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide. *Clinical Pharmacokinetics*, **1984**, 9 Suppl 1, 42-8	6.2	14
48	ITC Commentary on Metformin Clinical Drug-Drug Interaction Study Design That Enables an Efficacy- and Safety-Based Dose Adjustment Decision. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 781-784	6.1	14
47	Computational Discovery and Experimental Validation of Inhibitors of the Human Intestinal Transporter OATP2B1. *Journal of Chemical Information and Modeling*, **2017**, 57, 1402-1413	6.1	13
46	Deorphaning a solute carrier 22 family member, SLC22A15, through functional genomic studies. *FASEB Journal*, **2020**, 34, 15734-15752	0.9	13
45	Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP. *Molecular Pharmaceutics*, **2020**, 17, 748-756	5.6	12
44	Expression of a renal Na(+)-nucleoside cotransport system (N2) in Xenopus laevis oocytes. *Pflugers Archiv European Journal of Physiology*, **1994**, 427, 381-3	4.6	12
43	Unmet needs: Research helps regulators do their jobs. *Science Translational Medicine*, **2015**, 7, 315ps22	17.5	11
42	l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 2254-2258	2.9	10
41	GenEpi: gene-based epistasis discovery using machine learning. *BMC Bioinformatics*, **2020**, 21, 68	3.6	10
40	Formycin B elimination from the cerebrospinal fluid of the rat. *Pharmaceutical Research*, **1993**, 10, 611-5	4.5	10
39	Opportunities and challenges for the computational interpretation of rare variation in clinically important genes. *American Journal of Human Genetics*, **2021**, 108, 535-548	11	10
38	Human Concentrative Nucleoside Transporter 3 (hCNT3, SLC28A3) Forms a Cyclic Homotrimer. *Biochemistry*, **2017**, 56, 3475-3483	3.2	9
37	The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.. *Clinical Pharmacology and Therapeutics*, **2022**,	6.1	9
36	Pharmacogenetics of Antidiabetic Drugs. *Advances in Pharmacology*, **2018**, 83, 361-389	5.7	9

35	Taurine transport in cultured choroid plexus. *Pharmaceutical Research*, **1997**, 14, 406-9	4.5	8
34	A New Era in Pharmacovigilance: Toward Real-World Data and Digital Monitoring. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1197-1202	6.1	8
33	Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 323-325	6.1	7
32	Renal transport of drugs: an overview of methodology with application to cimetidine. *Pharmaceutical Research*, **1988**, 5, 465-71	4.5	7
31	Stereoselective binding of disopyramide to plasma proteins. *Pharmaceutical Research*, **1988**, 5, 316-8	4.5	7
30	Functional and structural analysis of rare SLC2A2 variants associated with Fanconi-Bickel syndrome and metabolic traits. *Human Mutation*, **2019**, 40, 983-995	4.7	6
29	Scientific considerations for global drug development. *Science Translational Medicine*, **2020**, 12,	17.5	6
28	OCT (SLC22A) and OCTN Family **2013**, 171-208		5
27	Mechanisms of 5-fluorouracil (5-FU) transport in isolated rabbit choroid plexus tissue slices. *Pharmaceutical Research*, **1996**, 13, 1276-8	4.5	5
26	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. *Diabetes Care*, **2021**, 44, 2673-2682	14.6	5
25	Effect of probenecid on the pharmacokinetics and pharmacodynamics of procainamide. *Journal of Clinical Pharmacology*, **1991**, 31, 429-32	2.9	4
24	.. *Drug Metabolism and Disposition*, **2021**,	4	4
23	Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3. *Journal of Pharmaceutical Sciences*, **2021**, 110, 347-353	3.9	4
22	Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 559-562	6.1	4
21	Research Projects Supported by the University of California, San Francisco-Stanford Center of Excellence in Regulatory Science and Innovation. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 815-818	6.1	3
20	Cimetidine elimination from the cerebrospinal fluid of the rat. *Pharmaceutical Research*, **1988**, 5, 628-33	4.5	3
19	Expanding Precompetitive Multisector Collaborations to Advance Drug Development and Pharmacogenomics. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 96-101	6.1	3
18	Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 108-122	6.1	3

17	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. *British Journal of Pharmacology*, **2021**, 178, 1459-1474	8.6	3
16	High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3.. *Pharmaceutical Research*, **2022**, 1	4.5	2
15	Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics. *Clinical and Translational Science*, **2021**, 14, 1431-1443	4.9	2
14	In Vitro Evaluation of Excipients as Inhibitors of Human Intestinal P-glycoprotein. *FASEB Journal*, **2019**, 33, 814.3	0.9	1
13	Neural production of kynurenic acid in requires the AAT-1 transporter. *Genes and Development*, **2020**, 34, 1033-1038	12.6	1
12	The Effects of Genetic Mutations and Drugs on the Activity of the Thiamine Transporter, SLC19A2. *AAPS Journal*, **2021**, 23, 35	3.7	1
11	Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. *AAPS Journal*, **2021**, 23, 106	3.7	1
10	Mechanisms and genetics of drug transport **2022**, 213-239		0
9	A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption.. *AAPS Journal*, **2022**, 24, 60	3.7	0
8	The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity **2018**, 15-24		
7	The Pharmacogenomics of Membrane Transporters Project **2013**, 73-108		
6	Verapamil interacts stereoselectively with the muscarinic receptor. *Pharmaceutical Research*, **1985**, 2, 94-5	4.5	
5	Pharmacogenomic mechanisms of drug toxicity **2022**, 303-322		
4	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. *Blood*, **2011**, 118, 571-571	2.2	
3	Germline Genetic Polymorphisms Are Associated with Disease-Free Survival in Adults with Acute Myeloid Leukemia (AML): A Genomewide Association Study From the Pgrn-Riken Global Alliance.. *Blood*, **2012**, 120, 2548-2548	2.2	
2	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682.. *Diabetes Care*, **2022**, 45, e82-e83	14.6	
1	ORGANIC CATION AND ZWITTERION TRANSPORTERS **2022**, 9-32		